HUP0200497A2 - Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treatment of certain cancers associated with weight gain - Google Patents

Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treatment of certain cancers associated with weight gain

Info

Publication number
HUP0200497A2
HUP0200497A2 HU0200497A HUP0200497A HUP0200497A2 HU P0200497 A2 HUP0200497 A2 HU P0200497A2 HU 0200497 A HU0200497 A HU 0200497A HU P0200497 A HUP0200497 A HU P0200497A HU P0200497 A2 HUP0200497 A2 HU P0200497A2
Authority
HU
Hungary
Prior art keywords
methylbutylamine
cyclobutyl
dimethyl
treatment
weight gain
Prior art date
Application number
HU0200497A
Other languages
English (en)
Hungarian (hu)
Inventor
Carl M Mendel
Timothy B Seaton
Steve P Weinstein
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of HUP0200497A2 publication Critical patent/HUP0200497A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0200497A 1999-03-19 2000-03-17 Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treatment of certain cancers associated with weight gain HUP0200497A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12525099P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
HUP0200497A2 true HUP0200497A2 (en) 2002-08-28

Family

ID=22418838

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200497A HUP0200497A2 (en) 1999-03-19 2000-03-17 Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treatment of certain cancers associated with weight gain

Country Status (19)

Country Link
EP (1) EP1171106A1 (ja)
JP (1) JP2002539255A (ja)
KR (1) KR20010113765A (ja)
CN (1) CN1399545A (ja)
AU (1) AU3632000A (ja)
BG (1) BG105998A (ja)
BR (1) BR0009161A (ja)
CA (1) CA2367045A1 (ja)
CZ (1) CZ20013281A3 (ja)
HU (1) HUP0200497A2 (ja)
IL (1) IL145239A0 (ja)
MX (1) MXPA01009470A (ja)
NO (1) NO20014478L (ja)
NZ (1) NZ514012A (ja)
PL (1) PL351958A1 (ja)
SK (1) SK13372001A3 (ja)
TR (1) TR200102692T2 (ja)
WO (1) WO2000056323A1 (ja)
ZA (1) ZA200107687B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096202A1 (en) * 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
TR200102692T2 (tr) 2002-03-21
EP1171106A1 (en) 2002-01-16
NZ514012A (en) 2001-09-28
BG105998A (en) 2002-06-28
CN1399545A (zh) 2003-02-26
PL351958A1 (en) 2003-07-14
CA2367045A1 (en) 2000-09-28
JP2002539255A (ja) 2002-11-19
IL145239A0 (en) 2002-06-30
WO2000056323A1 (en) 2000-09-28
SK13372001A3 (sk) 2002-07-02
KR20010113765A (ko) 2001-12-28
NO20014478L (no) 2001-10-29
NO20014478D0 (no) 2001-09-14
CZ20013281A3 (cs) 2002-07-17
MXPA01009470A (es) 2004-03-19
AU3632000A (en) 2000-10-09
BR0009161A (pt) 2002-01-22
ZA200107687B (en) 2002-12-18

Similar Documents

Publication Publication Date Title
GB2392382B (en) Body support system
IL153508A0 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
ZA200406645B (en) Supported silver catalyst and and epoxidation process using the catalyst
AU1463402A (en) Cushioned, fiber-covered dental applicators
HUP0201874A3 (en) Pesticidal indazole and benzotriazole derivatives, preparation and use thereof
ZA200003236B (en) Combination therapy for the treatment of migraine.
ZA200105293B (en) Use of growth hormone secretagogues for treatment of physical performance decline.
HUP0200501A2 (en) Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
HUP0200393A2 (en) Use of pharmaceutical composition containing n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for controlling weight gain associated with therapeutic drugs
AU8582301A (en) A catalyst support, a supported group viii metal catalyst and a precursor thereof, processes for their preparation, and use of the supported group viii metal catalyst
HK1047048A1 (en) Therapeutic use of melatonin.
HUP0200497A2 (en) Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treatment of certain cancers associated with weight gain
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
HUP0200494A2 (en) Use of-n,n-dimethyl-1-[1-(4 chlorophenyl)cyclobutyl]-3-metilbutilamine for treatment of osteoarthritis
ZA200203166B (en) Treatment of cancer.
IL157830A0 (en) Imidazolidine derivatives, their preparation, and their use as antinflammatory agent
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.
GR1004664B (en) The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
HUP0200498A2 (en) Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutyl amine for treatment of hiatial hernia
HUP0103778A3 (en) Process for preparing 1,5-diaryl-3-substituted pyrazoles
GB0221791D0 (en) Overseas stay support system
ZA200002343B (en) Combination therapy for the treatment of migraine.
HUP0200500A2 (en) Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for aiding weight loss after pregnancy
IL159561A0 (en) Eurotinones and derivatives thereof, processes for preparing them, and their use